IL-1β is not critical to chronic heart dysfunction in mice with Chagas disease

Camila Victória Sousa Oliveira1, Oscar Moreno-Loaiza2†, Daniel Figueiredo-Vanzan3, Isalira Peroba Ramos4, Hilton Mata-Santos3, Marcelo Torres Bozza1, Claudia Neto Paiva1* and Emiliano Medei2,4,5*

1Departamento de Imunologia, Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil, 2Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil, 3Faculdade de Farmácia, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil, 4National Center for Structural Biology and Bioimage (CENABIO), Federal University of Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil, 5D’Or Institute for Research and Education (IDOR), Rio de Janeiro, Brazil

Long after Trypanosoma cruzi infection, 40% of individuals develop a progressive chronic chagasic cardiomyopathy (CCC), with systolic dysfunction and arrhythmias. Since we previously showed IL-1β mediates the development of systolic dysfunction and cardiac arrhythmias in diabetes mellitus and cardiorenal syndrome, and IL-1β remains elevated in Chagas disease patients, here we tested the role of IL-1β in CCC using a mouse model. Mice deficient in IL-1R expression (Il-1r−/−) survived acute T. cruzi infection with greater parasitemia than controls but did not lose weight as wild-type (WT) did. At the chronic stage, WT presented prolonged ventricular repolarization intervals (QJ), while Il-1r−/− presented intervals like noninfected controls. Infected Il-1r−/− and WT did not differ in stroke volume (SV), the incidence of cardiac arrhythmias on electrocardiography (EKG), whole heart action potential duration (APD), or the incidence of triggered activity after S1–S2 protocol, which is a measure of susceptibility to cardiac arrhythmias. We also treated chronically infected WT mice with an IL-1R antagonist, anakinra. Treatment shortened the QJ interval but did not improve the SV or the incidence of cardiac arrhythmias on EKG. Anakinra failed to reduce triggered activity following the electrical extra-stimulation protocol. In conclusion, the absence of functional IL-1β/IL-1R signaling did not prevent or reverse the decrease of SV or the incidence of cardiac arrhythmias induced by chronic T. cruzi infection, implying this is not a critical mechanism in generating or maintaining CCC. Since similar cardiac abnormalities were previously credited to IL-1β signaling, ruling out this mechanism is important to discourage further attempts of IL-1β blockade as a therapeutical measure.
**Introduction**

*Trypanosoma cruzi* molecules are recognized by several pattern recognition receptors (PRRs) such as Toll- (TLRs), C-type lectin- (CLRs), and NOD-like receptors (NLRs), triggering an inflammatory response from innate immunity cells right after contamination. The inflammatory response during the acute phase contributes to activating innate trypanocidal mechanisms and prime/polarizing the T-cell response. After the establishment of an adaptive response, parasite burden is controlled, but not eliminated, and inflammation persists in several tissues such as the heart throughout the life of the chronically infected animal. In humans and in mice, myocarditis might progress after infection, producing heart disease. Systolic dysfunction, bradycardia, atrial fibrillation, ventricular tachycardia, and sinoatrial and atrioventricular blocks are all common findings in those individuals affected by chronic chagasic cardiomyopathy (CCC) (1, 2).

The inflammasome is a sensor of both microbe infections and sterile damage, which produces several function adaptations in the cardiovascular system (3, 4). Systolic dysfunction may arise from inflammasome activation and IL-1β production (5–8). In fact, several randomized clinical trials have addressed the potential of IL-1β blockade to treat heart failure (9–13). Also, arrhythmias may result from inflammasome activation, such as in atrial fibrillation driven by NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome activation in post-open-heart surgery (14) and in obesity (15). We have previously shown that renal ischemia-reperfusion triggers cardiac arrhythmia through NLRP3 inflammasome activation and IL-1β production (16), and in diabetes mellitus, the NLRP3 inflammasome connects metabolic dysfunction to cardiac arrhythmias through IL-1β production (17). Situations in which IL-1β works as a soluble intermediary linking inflammasome activation and cardiac dysfunction are particularly suitable for therapeutic intervention using a soluble antagonist of IL-1R, anakinra (Kineret).

The inflammasome is activated during *T. cruzi* infection. Despite surviving acute infection with Y strain *T. cruzi*, mice deficient in NLRP3 and caspase-1 present greater parasitemia than wild-type controls (18). Accordingly, macrophages from Nlrp3−/− and Caspase-1−/− mice infected in vitro with *T. cruzi* are less efficient in controlling parasite burden because of decreased autophagy and nitric oxide (NO) production (18, 19). The levels of IL-1β are decreased in plasma from infected Nlrp3−/− and Caspase-1−/− mice, and in fact, while NLRP3, caspase-1, and IL-18 contribute to NO production and parasitism control, IL-1β activity has no effect on macrophage parasitism (18). In mice infected with the Tulahuen strain, clearance of liver parasites is dependent on NLRP3 expression (20). Hepatic macrophages from infected Nlrp3−/− produce more reactive oxygen species (ROS) than that from wild-type mice (20), a factor that might underlie this susceptibility since oxidative stress fuels *T. cruzi* infection (21, 22). The secretion of IL-1β persists during chronic *T. cruzi* infection in patients with heart disease (23), but its role in CCC remains unknown.

Here, we tested whether IL-1β contributes to systolic dysfunction and cardiac arrhythmias in CCC. For this purpose, we infected Il-1r−/− and WT mice, and in addition, we treated chronically infected WT mice with the IL-1R-antagonist anakinra, assessing their cardiac function by electrocardiography (EKG) and echocardiography (ECHO). We also studied ventricular action potential at the whole heart level and the susceptibility to triggered activity after electrical stimulation protocol. Our results indicate that IL-1β is not critical to the generation/maintenance of cardiac arrhythmias or systolic dysfunction found in CCC.

**Results**

**The absence of a functional IL-1R leads to increased parasitemia but allows weight gain in Chagas disease**

To determine whether IL-1β was involved in the genesis of chronic heart dysfunction in mice, we infected young Il-1r−/− and wild-type (WT) mice (24) (6–8 weeks old, C57BL/6 background) with the Colombian strain of *T. cruzi* and monitored parasitemia and weight gain during the acute and chronic stages of infection.

During the acute stage (60 days postinfection (dpi)) Il-1r−/− mice reached greater parasitemia than WT mice (Figure 1A), confirming that IL-1β signaling during the acute stage contributes to reducing parasite burden. Total mortality at 210 dpi did not differ between groups (1/11 for infected Il-1r−/− mice and 1/19 for WT (p = 0.68)).

The plasma levels of IL-1β were significantly increased in *T. cruzi*-infected WT and Il-1r−/− mice compared to respective noninfected controls at 210 dpi (Figure 1B), demonstrating that the secretion of this cytokine is stimulated and remains elevated long after infection onset.

Infected WT mice started to lose weight a few months after infection and at 210 dpi had no increase in weight compared to the basal 6–8 weeks level. In contrast, noninfected WT controls continued to gain weight, as did both infected and noninfected Il-1r−/− mice (Figure 1C).

Taken together, these results indicate that IL-1β signaling through IL-1R contributes to controlling parasite growth and to the previously described cachexia during acute Chagas disease (25).
IL-1β signaling through IL-1R is active during the acute stage, and its constitutive absence is not critical to cardiac function in the chronic stage. Wild-type (WT) and Il-1r−/− mice (C57BL/6 background) were infected with the Colombian strain of T. cruzi (sum of two independent experiments with similar parasitemias, 50 and 200 parasites/inoculum) at 6–8 weeks of age. (A) Parasitemia (4–10 mice per group). (B) Serum levels of IL-1β (210 dpi, 3–6 mice per group). (C) Body weight gain (3–10 mice per group). (D) Echocardiography (210–270 dpi, 10–17 mice per group): ejection fraction (EF), stroke volume (SV), left ventricle diastolic volume (LVDV), right ventricle area (RV), and left ventricle area (LV). (E) The relative weight of the heart (heart weight mg/tibia length mm). Data represent the mean ± SEM. *p < 0.05.
The absence of a functional IL-1R prevents both bradycardia and prolongation of ventricle repolarization interval but is not involved in other Chagas disease arrhythmias

The typical findings at the chronic stage of murine Chagas disease are a decrease in ejection fraction (EF), stroke volume (SV), dilation of the right ventricle (RV), bradycardia, and an increase in the duration of P wave, PR interval, and QI interval. These alterations mimic the clinical stages B1–B2 described in humans (26). We assessed the cardiac function of infected WT and Il-1r−/− by EKG and ECHO during chronic Chagas disease (210–270 dpi, pooled data). We compared noninfected versus infected mice among both WT and Il-1r−/− groups and also infected WT versus infected Il-1r−/− mice.

The alterations in ventricular function previously described by us at the chronic stage of the Colombian infection in BALB/c (27) were found here in the C57BL/6 background (WT, by 210–270 dpi): a significant decrease in EF and SV, accompanied by RV dilation (Figure 1D). Similar alterations were also found in infected Il-1r−/− mice (Figure 1D). A slight (9%), nonsignificant (p = 0.08) increase in the relative weight of the heart (heart mg/tibia mm) was observed in WT infected versus noninfected, but less so in Il-1r−/− infected versus noninfected mice (Figure 1E).

At the chronic stage, while infected WT mice presented bradycardia, infected Il-1r−/− mice preserved a heart rate like noninfected controls (Figure 2A). The duration of the P wave was significantly increased in infected Il-1r−/− mice compared to noninfected controls, but not in infected WT mice (Figure 2B). In addition, the PR interval was 58% greater in infected Il-1r−/− compared to noninfected mice, but only 22% in infected WT mice, indicating that the absence of a functional IL-1R causes a trend toward decreased conduction speed from the SA node to the Bundle of His in Chagas disease. On the other hand, the QI interval (early repolarization, which is produced by K+ efflux and once prolonged, sensitizes to ventricular arrhythmias (28)) was significantly prolonged in infected WT but not in infected Il-1r−/− mice, indicating that IL-1β signaling through IL-1R is critical to prolonging ventricle repolarization interval in Chagas disease (Figures 2A, B).

The EKG traces of infected and noninfected mice are shown in Figure 2A, with intervals depicted. A low-voltage QRS was previously described in both human and murine Chagas disease and found in both infected WT and Il-1r−/− traces (Figure 2A).

Several arrhythmic events were detected in infected mice, such as second- and third-degree atrioventricular (AV) block, ventricular and supraventricular extrasystole, ventricular tachycardia, and traces with combined arrhythmias, such as AV block + ventricular tachycardia and AV block + ventricular bigeminy (Figure 2B). An even distribution of different arrhythmic events was found among infected WT and Il-1r−/− mice (Supplementary Table SI depicts each kind of arrhythmic event detected by us, its prevalence among infected mice in %, and the size of the mouse group n). The percentage of mice presenting arrhythmias was similar between infected WT and Il-1r−/− mice (Figure 2C).

These results indicate that IL-1β signaling through IL-1R produces adaptations in heart rate and ventricle repolarization in Chagas disease but is not directly involved in producing other arrhythmias.

### Table SI

| Arrhythmic Event          | Prevalence in % | Size of Mouse Group |
|---------------------------|-----------------|---------------------|
| Ventricular arrhythmias   |                 |                     |
| Ventricular extrasystole  |                 |                     |
| Atrioventricular block    |                 |                     |
| Supraventricular extrasystole |           |                     |
| Ventricular tachycardia   |                 |                     |
| AV block                  |                 |                     |
| Ventricular bigeminy      |                 |                     |

### Action potential duration and ventricular-triggered activities do not depend on IL-1R in Chagas disease

As described by Medei et al. (29, 30), CCC produces alterations in ventricular repolarization. We have also previously demonstrated that IL-1β represents the immunological link between ventricular arrhythmias and type-1 diabetes. Here, we tested whether IL-1β is involved in the ventricular arrhythmias described in CCC.

An increase in ventricular action potential duration (APD) (210 dpi) at 30% (APD 30, p = 0.037) and 50% (APD 50, p = 0.037) of repolarization was observed comparing WT infected versus noninfected hearts (Figures 3A, B). These data indicate that phase 1 of AP is slower in infected than in noninfected WT mice (Figure 3A). A similar, though less pronounced phenomenon occurred among infected versus noninfected Il-1r−/− hearts at APD 30 (p = 0.09). Nevertheless, APD 70 and APD 90 presented a nonsignificant trend towards decreased mean values in infected versus noninfected hearts from both the WT and Il-1r−/− groups.

We tested the susceptibility to ventricular arrhythmic events, like triggered activities and early- or delayed-afterdepolarizations, using an electrical extra-stimulation protocol (S1–S2), which gradually shortens the interval between S1 and S2 stimuli, paced at 5 Hz. Hearts from infected WT and Il-1r−/− mice presented similar susceptibility to triggered activity (Figure 3C). Also, the S1–S2 protocol evoked a close incidence of ventricular arrhythmias in whole hearts from the WT and Il-1r−/− groups (Figure 3D), 85.7% of the hearts from WT+Tc were affected, while among Il-1r−/−+Tc mice, 100%.

These results demonstrate that while the lack of IL-1R might produce slight differences in APD, it is not enough to prevent ventricular susceptibility to arrhythmias, suggesting that other players are more critically involved in this process.

### Treatment with anakinra does not interfere much with ventricular function

Treatment with anakinra prevented new heart failure events in experimental and randomized clinical trials (31). Since the
IL-1R deficiency prevents bradycardia and prolongation of ventricle repolarization but is not involved in Chagas disease arrhythmias. Wild-type (WT) and IL-1r−/− mice (C57BL/6 background) were infected with the Colombian strain of T. cruzi (sum of two independent experiments with similar parasitemias, 50 and 200 parasites/inoculum). Electrocardiography was performed at the chronic stage (210–270 dpi).

(A) Representative EKG tracings; (B) heart rate, P wave, PR interval, and QJ interval duration (9–22 mice per group, data represent mean ± SEM). (C) Identified arrhythmic events and incidence of arrhythmias among chronically infected mice. Atrioventricular block (AV block), sinus complex (S), ventricular complex (V), ventricular tachycardia (VT), p wave (p), masked p wave (p*).
outcome of infection in the constitutive absence of IL-1R reflect the role of IL-1β in the generation of CCC, which based on our results, seems to be of little relevance, we performed IL-1R blockade in infected WT mice. Targeting IL-1R with anakinra offers a translational opportunity to test whether it can reverse established CCC and thus have a therapeutical potential. We treated C57BL/6 mice with well-established CCC (240-270 dpi, pooled data) with anakinra, for 30 days, and assessed their ventricular function.

Though treatment with anakinra did not significantly alter survival (Figure 4A), weight gain (Figure 4B), or IL-1β plasma levels (Figure 4C) during the chronic stage, there was a visual clinical improvement, with less pronounced disease signals such as prostration, bald spots, ruffled fur, and hunched back (Figure 4D). Such general health improvement was accompanied by a normal relative heart weight, contrasting with increased ones found among nontreated infected controls (Figure 4E).
FIGURE 4
Treatment of chronically infected mice with anakinra (IL-1R antagonist) improves general health but not systolic function. C57BL/6 mice were infected with the Colombian strain of *T. cruzi* (100–200 parasites) and at chronic stage (240–270 dpi), treated with anakinra (10–25 mg/kg, i.p., sum of two independent experiments with 100 and 200 parasites/inoculum). (A) Survival curve. (B) Percentage of body weight gain. (C) Serum levels of IL-1β. (D) Less pronounced disease signals such as prostration, bald spots, ruffled fur and hunched back. (E) The relative weight of the heart (heart mg/tibia mm). (F) Echocardiography: ejection fraction (EF), stroke volume (SV), left ventricle diastolic volume (LVDV), right ventricle area (RV), and left ventricle area (LV). Data represent the mean ± SEM from 11 to 15 mice per group. NI, noninfected; Tc, chronically infected mice; Tc+AK, chronically infected mice treated with anakinra.
Treatment of infected mice with anakinra recovered EF (Figure 4F), but this recovery was neither due to a mean increase in SV nor to a mean decrease in LVDV, which did not differ significantly from nontreated infected controls but produced increased SV/LVDV ratios (EF).

A similar RV dilation was found in both infected groups, nontreated and anakinra-treated mice (Figure 4F). No differences were found in LV among groups.

Taken together, these results show anakinra did not significantly improve cardiac ventricular function, even though general health seemed to have improved.

Treatment with anakinra does not greatly alter ventricular arrhythmia susceptibility or cardiac conduction disturbances

Treatment with anakinra reverses cardiac electrical disturbances in T1 diabetes mellitus (17) and cardiorenal syndrome (16) in mice. Since in Chagas disease the IL-1β levels are increased (23), as we also observed here, we tested the hypothesis that anakinra would reverse the electrical disturbances induced by *T. cruzi* infection in a well-established CCC model.

Treatment of *T. cruzi*-infected mice with anakinra for 30 days starting at the chronic stage (240–270 dpi, pooled data) shortened ventricular repolarization interval (QJ, Figures 5A, B), an important electrical disturbance described in CCC, and reduced diffuse and focal inflammatory infiltrates/associated interstitial and perivascular fibrosis (Supplementary Figure 1). However, a prolonged PR interval was still observed in hearts from anakinra-treated mice, like those in infected, untreated mice. Moreover, infected mice treated with anakinra presented a similar percentage of ventricular arrhythmic events and similar abnormal electrical conduction when compared to infected untreated mice (Figure 5C).

To study in depth the cellular mechanisms involved in shortening QJ interval, an AP recording in the left ventricle was performed in isolated whole hearts. Treatment with anakinra was able to reverse the changes induced in the APD at the chronic stage (Figures 5D, E). However, at an intact heart level, the susceptibility to triggered activities upon extrastimulation protocol (S1–S2) did not change in response to *in vivo* blockade of IL-1β. Blockade of IL-1β signaling did not improve stroke volume. These results indicate that IL-1β is not critically involved in the genesis and maintenance of Chagas disease cardiac dysfunction.

We found a shortening of the ventricular repolarization interval (QJ) in infected IL-1r−/− compared to WT mice and also in infected WT after treatment with anakinra. However, there was no reduction in the incidence of arrhythmias in chronically infected IL-1r−/− mice or after treatment of chronically infected WT mice with anakinra. The triggered activities upon extrastimulation protocol (S1–S2) did not change in response to *in vivo* blockade of IL-1β. Blockade of IL-1β signaling did not improve stroke volume. These results indicate that IL-1β is not critically involved in the genesis and maintenance of Chagas disease cardiac dysfunction.

The role of IL-1β production in adapting heart function to both sterile and infectious inflammatory conditions has been extensively described in the literature (7, 32, 33). An ongoing phase 2 clinical trial is even assessing the therapeutic potential of IL-1R blockade with anakinra to treat heart failure (34). Along with TNF and IL-6, IL-1 (not mature IL-1β) was indicated as a factor involved in delayed repolarization, long QT syndrome, and ventricular tachycardia (35). In 2016, we demonstrated that exposure of isolated ventricular rat cardiomyocytes to IL-1β reduced transient outward potassium current (Ito), a key repolarizing current, thereby prolonging APD and providing a substrate for triggered arrhythmogenic activity (17). Exposure to IL-1β increased diastolic leak of Ca2+ from the sarcoplasmic reticulum (SR) and spontaneous contractile events, an index of arrhythmic events. Also, the absence of a functional IL-1R expression prevents QT prolongation, and treatment with anakinra decreases arrhythmia scores in diabetes mellitus. In renal ischemia/reperfusion, IL-1β produced after sensing kidney injury prolongs QJ and sensitizes to cardiac arrhythmias (16).

Therefore, there is a strong case for IL-1β being involved in the genesis and maintenance of heart insufficiency and cardiac arrhythmias, but we found here that it is not the case for CCC.

Since other studies found a role for TNF in ventricular and electrical function in CCC (36), and since TNF, IL-1β, and IL-6 are often involved in ventricular tachycardia (37–39), we believe the focus of future studies should be to simultaneously target TNF, IL-6, and IL-1β (40) in order to assess the role of these usually cooperative cytokines in CCC.

While infection of IL-1r−/− mice provides a model in which no IL-1β signaling is allowed since the onset of infection, it fails to exclude differences in heart physiology/immunological response that might reflect the role of IL-1β in mouse development. However, both infection of IL-1r−/− mice and IL-1R blockade with anakinra starting at chronic infection resulted in reduced QJ compared respectively to WT or nontreated controls. These data indicate that IL-1β production evoked by infection is involved in generating and maintaining a prolonged QJ interval in CCC.

Several health parameters pointed towards a general improvement in the absence of IL-1β/IL-1R signaling during CCC. The cachexia that ensues from *T. cruzi* infection did not occur in IL-1r−/− mice, an unexpected finding, since it has been
FIGURE 5
Treatment of chronically infected mice with anakinra (IL-1R antagonist) does not reverse arrhythmias. Wild-type (WT) (C57BL/6 background) were infected with the Colombian strain of *T. cruzi* (100 parasites) at 270 dpi and treated with an IL-1R antagonist, anakinra (10 mg/kg, i.p.), daily for 30 days. (A) Representative EKG tracings. (B) Heart rate, P wave, PR interval, and QJ interval duration (9–22 mice per group, data represent the mean ± SEM). (C) Identified arrhythmic events. (D) Representative whole heart AP traces. (E) Whole heart AP duration at 30%, 50%, 70%, and 90% of repolarization (4–14 mice per group). (F) Incidence of triggering activity among hearts from groups of mice upon S1–S2 protocol. (G) Representative tracing showing triggering activity in a Tc+AK heart. NI, noninfected; Tc, chronically infected mice; Tc+AK, chronically infected mice treated with anakinra.
solely credited to TNF signaling (25). These findings follow the same pattern already found in *Toxoplasma gondii* infection, in which cachexia has been recently credited to IL-1β (41). Although blockade of IL-1R with anakinra for 30 days did not produce weight gain, it did result in improvement of clinical signals and reversed the increase in heart relative weight. These findings deserve further studies focusing on the role of IL-1β on cachexia and general health during *T. cruzi* infection to be confirmed.

A limitation of our work concerns the variation of the parasite burden after treatment of chronically infected mice with anakinra. An increase in parasite burden after IL-1R blockade could potentially compensate for the beneficial effects of such blockade on cardiac function. Although we cannot rule out variations in heart parasitism after treatment with anakinra, we do not believe it is the case since no detectable heart parasitism was found in HE sections from their hearts, but instead, we detected a decrease in the number of inflammatory cells infiltrating their hearts. Previous works showed lack of IL-1R expression does not prevent trypanocidal NO production by macrophages (18), but in our experiments, the absence of IL-1R expression produces greater parasitemia during the acute stage and we did not assess the chronic heart parasitism. There are currently no works systematically approaching the role of IL-1R in controlling established heart parasitism at the chronic stage of Chagas disease.

One could argue that treatment with anakinra is futile because once CCC is well-established, systolic dysfunction and arrhythmias cannot be reversed, since they result from the destruction of heart tissue. However, there are several demonstrations in the literature that cardiac dysfunction in experimental CCC can be reversed even when attempted late after infection. We have previously shown a great improvement in systolic function, an increase in heart rate, and partial reversal of right ventricle dilation and conduction blocks/arrhythmias after treating chronically infected mice with resveratrol (27). Treatment prorogation or treatment with resveratrol late after infection onset (120 dpi) also resulted in improvements in heart function. Treatment of chronically infected mice with Met-RANTES, an analog of CCL3 that blocks CCR1/CCR5 receptors, reduced PR and QTc prolongation, and partially reversed bradycardia (42). Our results here show that IL-1R blockade does not improve systolic function or reverse cardiac arrhythmias, indicating IL-1β/IL-1R signaling is not involved in its maintenance, as it is in other diseases (16, 17).

Strategies to reverse cardiac dysfunction at the chronic stage, such as IL-1R antagonists, are particularly suitable to treat Chagas disease since it is usually diagnosed late after infection. Currently, there are no specific treatments for CCC, and treatment is solely an extension of usual treatments for heart failure and arrhythmias. Despite shortening of QJ ventricle repolarization interval, a known substrate for arrhythmias, IL-1R blockade failed to reduce the incidence of arrhythmias/
first treated a group of mice with a 10-mg/kg dose. In the face of the lack of beneficial effect, we increased the dose to 25 mg/kg. Since the results were similar and there was no dose dependence, we plotted all these results together.

**Transthoracic echocardiography**

To assess cardiac ventricular function, an echocardiogram was performed. Mice under deep isoflurane anesthesia (2% in oxygen) were trichotomized in the precordial region using depilatory cream. The study was performed using a 30-Mhz transducer with a Vevo 770 Ultrasound apparatus (Visual Sonics, Toronto, Canada). The left ventricle ejection fraction (LVEF) was calculated using Simpson’s method, chosen because of its fit with CD heart geometry and because it is commonly used to assess CD patients. The areas of the left and right ventricles during diastoles and systoles were obtained in B mode using a short-axis view at the level of the papillary muscles.

**Electrocardiography**

EKG signals were recorded as previously described (27). Mice were sedated with diazepam (10 mg/kg), and electrodes were placed subcutaneously (DI derivation). Traces were recorded using the Power-Lab 2/20 System connected to an amplifier (Panlab Instruments, Spain) at a sample rate of 1 kHz.

The analysis of EKG recordings was performed in Trace-Watcher (43), a custom Lab-View–based Software (National Instruments, USA) designed and gently provided to us by Dr. Ariel Escobar (UC-Merced, USA). Briefly, EKG signals were filtered with a Gaussian filter at a 0.2-kHz cutoff value, then the baseline was corrected, and the signals were segmented in windows containing the whole cardiac cycle. The P wave, PR interval, and QJ duration were measured. Additionally, R peak locations were automatically detected and then adjusted by a trained observer using PhysioZoo software (44). Spontaneous cardiac arrhythmias were evaluated by a trained observer during the whole recording.

**Ventricular action potential recordings at a whole-heart level**

To evaluate epicardial left ventricular action potentials (APs), sharp glass microelectrodes were used as previously described (16). Fifteen minutes prior to euthanasia, mice were injected with 1,000 UI of heparin (i.p., Cristalia, São Paulo, Brazil) to prevent clot formation. Animals were euthanized by cervical dislocation. Hearts were then quickly removed and gently washed in Tyrode’s solution containing (in mM) the following: 140 NaCl, 5.4 KCl, 2.0 CaCl2, 1.0 MgCl2, 10.0 D-glucose, 0.33 Na2HPO4, 10.0 HEPES (pH 7.4 ± 0.02 adjusted NaOH at 37.0°C). The aorta was cannulated in a Langendorff system and immediately perfused with oxygenated Tyrode’s solution. After 10–15 min of the stabilization period, the temperature was progressively increased from room temperature to 35.5°C–37°C, and blebbistatin 4 μM (Selleckchem, USA) was added to Tyrode’s solution to avoid mechanical artifacts during the AP recording. AP was recorded using a sharp borosilicate microelectrode (WPI, USA) filled with KCl to 3M and an approximate resistance of 15–20 MΩ connected to a high impedance microelectrode amplifier (Electro 705, WPI, USA). The signal was digitalized at a 2.5-kHz sampling frequency and recorded using LabView custom-designed software. All APs were recorded by the S1S1 pacing protocol at 5 Hz by a pulse generator (Digitimer DS2A, UK).

APs were analyzed in a custom LabView-based program (Trace-Watcher) developed and kindly provided by Dr. Ariel Escobar (43). First, signals were filtered with a Gaussian filter at 2 kHz. APs were individualized and normalized between 0 and 1. APD was measured at 30%, 50%, 70%, and 90% of repolarization. The average of approximately 180 AP traces was considered representative for each animal.

To test ventricular susceptibility to arrhythmias, we performed an extra-stimulation protocol. Hearts were paced at 5 Hz (S1) and then an extra stimulus (S2) was added. The S1–S2 period was gradually reduced. When an arrhythmic event was evoked, the stimulus was torn off.

**Statistics**

Statistical analysis was performed using Prism v 8.0 (GraphPad, USA). Data are shown in bar graphs as mean and standard error of the mean (SEM). Means were compared using Student’s t-test. The comparison between proportions of arrhythmic events across groups was calculated using Fisher’s exact test. p-values ≤0.05 were considered statistically significant. Significant differences are marked in each graph (*).

**Data availability statement**

The datasets analyzed for this study are available from the corresponding authors upon reasonable request.

**Ethics statement**

This study was carried out in strict accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals of the Brazilian National Council of Animal Experimentation (http://www.cobea.org.br/) and Federal Law 11.794 (October 8, 2008); The institutional Committee for Animal Ethics of UFRJ (CEUA, 005/2014).
Author contributions

CP and EM designed the study. CO, OM-L, D-FV, IPR, and HM-S performed the experiments. CO, OM-L, MB, CP, and EM analyzed the data. OM-L, CP and EM wrote the first version of the manuscript. All authors reviewed critically the manuscript and approved its final version of the manuscript.

Funding

OM-L received doctoral scholarship from Carlos Chagas Filho Foundation for Supporting Research in the State of Rio de Janeiro (FAPERJ) E26/200.396/2020. MB and EM received personal PQ CNPq grants. MB received grants E-26/210.155/2020, E-26/203.169/2017, E-26/210.191/2020, and E-26/210.253/2020; CNPq 310681/2018-9. MB received financial support from CNE E-26/201.128/2022(272688) and E-26/211.564/2019 (252360) e Pensa Rio FAPERJ.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Acquatella H. Echocardiography in chagas heart disease. Circulation (2007) 115:1124–31. doi: 10.1161/CIRCULATIONAHA.106.627323

2. Brito BOF, Ribeiro ALP. Electrocardiogram in chagas disease. Rev Soc Bras Med Trop (2018) 51:570–7. doi: 10.1590/0037-8682-0184-2018

3. Van Wagoner DR, Chung MK. Inflammation, inflammation activation, and atrial fibrillation. Circulation. (2018) 138:2243–6. doi: 10.1161/CIRCULATIONAHA.118.036143

4. Wang Y, Liu X, Shi H, Yu Y, Yu Y, Li M, et al. NLRP3 inflammasome, an immune-inflammatory target in pathogenesis and treatment of cardiovascular diseases. Clin Transl Med (2020) 10:91–106. doi: 10.1002/ctm2.13

5. Bracey NA, Beck PL, Muruve DA, Hirota SA, Guo J, Jabagi H, et al. The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1beta. Exp Physiol (2013) 98:462–72. doi: 10.1113/expphysiol.2012.088338

6. Carbone S, Mauro AG, Prestamburgo A, Halquist MS, Narayan P, Potere N, et al. An orally available NLRP3 inflammasome inhibitor prevents Western diet-induced cardiac dysfunction in mice. J Cardiovasc Pharmacol (2018) 72:303–7. doi: 10.1097/FJC.0000000000000628

7. Toldo S, Mauro AG, Cutter Z, Van Tassell BW, Mezzaroma E, Del Buono MG, et al. The NLRP3 inflammasome inhibitor, OCT177 (Dapansultane), reduces infarct size and preserves contractile function after ischemia reperfusion injury in the mouse. J Cardiovasc Pharmacol (2019) 73:215–22. doi: 10.1097/FJC.0000000000000858

8. Shang L, Yue W, Wang D, Weng X, Hall ME, Xu Y, et al. Systolic overload-induced pulmonary inflammation, fibrosis, oxidative stress and heart failure progression through interleukin-1beta. J Mol Cell Cardiol (2020) 146:84–94. doi: 10.1016/j.yjmcc.2020.07.008

9. Abbate A, Kontos MC, Grizzard JD, Biondi-Zoccai GG, Van Tassell BW, Rohati R, et al. Interleukin-1 blockage with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia commonwealth university anakinra remodeling trial [VCU-ART] pilot study). Am J Cardiol (2010) 105:1371–1377.e1371. doi: 10.1016/amjcard.2009.12.059

10. Abbate A, Van Tassell BW, Biondi-Zoccai G, Kontos MC, Grizzard JD, Spellman DW, et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia commonwealth university-anakinra remodeling trial (2) (VCU-ART2) pilot study]. J Am Cardiol (2013) 111:1394–400. doi: 10.1016/j.amjcard.2013.01.287

11. Van Tassell BW, Abouzaki NA, Oddi Erdle C, Carbone S, Trankle CR, Melchor RD, et al. Interleukin-1 blockade in acute decompensated heart failure: A randomized, double-blinded, placebo-controlled pilot study. J Cardiovasc Pharmacol (2016) 67:544–51. doi: 10.1097/FJC.0000000000000378

12. Van Tassell BW, Canada J, Carbone S, Trankle C, Buckley L, Oddi Erdle C, et al. Interleukin-1 blockade in recently decompensated systolic heart failure: Results from REEPHART (Recently decompensated heart failure anakinra response trial). Circ Heart Fail (2017) 10:1–23. doi: 10.1161/CIRCHEARTFAILURE.117.004373

13. Abbate A, Trankle CR, Buckley LF, Lipinski MJ, Appleton D, Kadariya D, et al. Interleukin-1 blockade inhibits the acute inflammatory response in patients with ST-Segment-Elevation myocardial infarction. J Am Heart Assoc (2020) 9: e014941. doi: 10.1161/JAHA.119.014941

14. Heijman J, Muna AP, Velvra T, Molina CE, Suzanto H, Tekko M, et al. Atrial myocyte NLRP3/CaMKII nexus forms a substrate for postoperative atrial fibrillation. Circ Res (2020) 127:1036–55. doi: 10.1161/CIRCRESAHA.120.316710

15. Scott L,F, Fender AC, Salic A, Li L, Chen X, Wang X, et al. NLRP3 inflammasome is a key driver of obesity-induced atrial arrhythmias. Cardiovasc Res (2021) 117:1746–59. doi: 10.1093/cvr/cvab024

16. Alarcón MML, Trenint-Sonoda M, Panico K, Schleier Y, Duque T, Moreno-Loaiza O, et al. Cardiac arrhythmias after renal I/R depend on IL-1beta. J Mol Cell Cardiol (2019) 131:101–11. doi: 10.1016/j.yjmcc.2019.04.025

17. Monnerat G, Alarcon ML, Vasconcellos LR, Hochman-Mendez C, Brasil G, Monnerat G, et al. Cardiac arrhythmias with ST-Segment-Elevation myocardial infarction. Nat Commun (2016) 7:13344. doi: 10.1038/ncomms13344

18. Gonçalves VM, Matteucci KC, Buzzo CL, Miolito BH, Ferrante D, Torrecillas AC, et al. NLRP3 controls trypanosoma cruzi infection through a

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.1010257/full#supplementary-material
capase-1-dependent IL-1R-independent NO production. *Flu Negl Trop Dis* (2013) 7:e2469. doi: 10.3714/journal.pntd.0002469

19. Matteucci KC, Pereira GJS, Weinrich R, Bortoluci KR. Frontline science: Autophagy is a cell autonomous effector mechanism mediated by NLRP3 to control trypanosoma cruzi infection. *J Leukoc Biol* (2019) 106:531-40. doi: 10.1002/jlb.H1118-461R

20. Paroli AF, Gonzalez PV, Diaz-Lujan C, Onofrio LL, Aracena A, Cano RC, et al. NLRP3 inflammasome and capase-1/11 pathway orchestrate different outcomes in the host protection against trypanosoma cruzi acute infection. *Front Immunol* (2018) 9:913. doi: 10.3389/fimmu.2018.00913

21. Paiva CN, Feijo DF, Dutra FF, Carneiro VC, Freitas GR, Alves LS, et al. Oxidative stress fuels trypanosoma cruzi infection in mice. *J Clin Invest* (2012) 122:2531–42. doi: 10.1172/JCIIS8525

22. Paiva CN, Medei E, Bozza MT. ROS and trypanosoma cruzi: Fuel to infection, poison to the heart. *PloS Pathog* (2018) 14:e1006928. doi: 10.1371/journal.ppat.1006928

23. Sousa GR, Gomes JA, Fares RC, Damasio MP, Chaves AT, Ferreira KS, et al. Plasma cytokine expression is associated with cardiac morbidity in chagas disease. *PloS One* (2014) 9:e87082. doi: 10.1371/journal.pone.0087082

24. Norman JG, Fink GW, Sexton C, Carter G. Transgenic animals demonstrate a role for the IL-1 receptor in regulating IL-1 beta gene expression at steady-state and during the systemic stress induced by acute pancreatitis. *J Surg Res* (1996) 63:231–6. doi: 10.1006/jare.1996.0253

25. Truyens C, Torrico F, Angelo-Barrion A, Luca R, Heremans H, De Baetselier P, et al. The cachexia associated with trypanosoma cruzi acute infection in mice is attenuated by anti-TNF-alpha, but not by anti-IL-6 or anti-IFN-gamma antibodies. *Parasite Immunol* (1995) 17:561–8. doi: 10.1111/j.1365-3024.1995.tb00999.x

26. Healy C, Viles-Gonzalez JF, Sexton C, Heremans H, De Baetselier P. Anti-TNF-alpha ameliorates chagasic heart disease in mice: Role of TNF-alpha in regulating cardiac function. *Front Immunol* (2016) 7:521–68. doi: 10.3389/fimmu.2015.00316

27. Vilar-Pereira G, Carneiro VC, Mata Santos IL, Vicentino AR, Ramos JP, Girola NL, et al. Resveratrol reverses functional chagas heart disease in mice. *PloS Pathog* (2016) 12:e1005947. doi: 10.1371/journal.ppat.1005947

28. Lopez Alarcon MM, Rodriguez De Yurre A, Felice JI, Medei E, Escobar AL. Phase 1 repolarization rate defines Ca(2+) dynamics and contractility on intact mouse hearts. *J Gen Physiol* (2019) 151:771–85. doi: 10.1016/j.jgp.2006.03.022

29. Medei E, Pedrosa RC, Benchimol Barbosa PR, Costa PC, Hernandez CC, Chaves EA, et al. Human antibodies with muscarinic activity modulate ventricular repolarization: basis for electrical disturbance. *Int J Cardiol* (2007) 115:373–80. doi: 10.1016/j.ijcard.2006.07.038

30. Medei EH, Nascimento JH, Pedrosa RC, Barcellos L, Masuda MO, Sicouri S, et al. Antibodies with beta-adrenergic activity from chronic chagas patients modulate the QT interval and m cell action potential duration. *Eur J Physiol* (2008) 456:868–76. doi: 10.1007/JF.0000000000001240

31. Del Bueno MG, Damonte JJ, Chiabrando JG, Markley B, Turington J, Trankle CR, et al. Effect of IL-1 blockade with anakinra on heart failure outcomes in patients with anterior versus nonanterior ST elevation myocardial infarction. *J Cardiovasc Pharmacol* (2022) 79:774–80. doi: 10.15190/c.p.2015.33

32. Frangogiannis NG. Interleukin-1 in cardiac injury, repair, and remodeling: pathophysiological and translational concepts. *Discoveries (Otsuval)* (2015) 3:1–11. doi: 10.1152/aphyrev.00158.2018

33. Toldo S, Mauro AG, Cutter Z, Abate A. Inflammammasome, pyroptosis, and cytokines in myocardial ischemia-reperfusion injury. *Am J Physiol Heart Circ Physiol* (2018) 315:H1533–68. doi: 10.1152/ajpheart.00267-02.03466-9

34. Van Tassell B, Mihalick V, Thomas G, Mazawan A, Talsaz AH, Lu J, et al. Rationale and design of interleukin-1 blockade in recently decompensated heart failure (REDHART2): a randomized, double blind, placebo controlled, single center, phase 2 study. *J Transl Med* (2022) 20:270. doi: 10.1186/s12967-022-03466-9

35. Sordillo PP, Sordillo DC, Nelson L. Review: The prolonged QT interval: Role of pro-inflammatory cytokines, reactive oxygen species and the ceramide and sphingosine-1 phosphate pathways. *In Vivo* (2015) 29:619–36

36. Pereira IR, Vilar-Pereira G, Silva AA, Moreira OC, Britto C, Sarmento ED, et al. Tumor necrosis factor is a therapeutic target for immunological unbalance and cardiac abnormalities in chronic experimental chagas' heart disease. *Mediators Inflammation* (2014) 2014:798078. doi: 10.1155/2014/798078

37. Lazzerini PE, Capecchi PL, Laghi-Pasini F. Systemic inflammation and arrhythmic risk: lessons from rheumatoid arthritis. *Eur Heart J* (2017) 38:1717–27. doi: 10.1093/heartjnl/hen11079

38. Lazzerini PE, Laghi-Pasini F, Bertolozzi I, Morozzi G, Lorenzini S, Simpatico A, et al. Systemic inflammation as a novel QT prolonging risk factor in patients with tobrus/de pointes. *Heart* (2017) 103:18–21. 10.1177/0142305216657053

39. Lazzerini PE, Laghi-Pasini F, Bertolozzi I, Morozzi G, Lorenzini S, Simpatico A, et al. Systemic inflammation as a novel QT prolonging risk factor in patients with torsades de pointes. *Heart* (2017) 103:18–21. 10.1177/0142305216657053

40. Hasselbach L, Weidner J, Elsasser A, Theilmann G. Heart failure relapses in response to acute stresses - role of immunological and inflammatory pathways. *Front Cardiowvasc Med* (2022) 9:809935. doi: 10.4049/fmmu.2020.00306

41. Melchor SJ, Saunders CM, Sanders I, Hatter JA, Byrnes KA, Coutermarsh-Ott S, et al. IL-1 regulates disease tolerance and cachexia in toxoplasma gondii infection. *J Immunol* (2020) 204:3329–38. doi: 10.3389/fimmu.2020.03006

42. Gibaldi D, Vilar-Pereira G, Pereira IR, Silva AA, Barrios LC, Ramos JP, et al. CCL3/Macrophage inflammatory protein-1 alpha is dually involved in parasite persistence and induction of a TNF- and IFN-gamma-enriched inflammatory milieu in trypanosoma cruzi-induced chronic cardiomyopathy. *Front Immunol* (2020) 11:306. doi: 10.1186/s13322-020-03466-5

43. Frangogiannis NG. Interleukin-1 in cardiac injury, repair, and remodeling: pathophysiological and translational concepts. *Discoveries (Otsuval)* (2015) 3:1–11. doi: 10.1152/aphyrev.00158.2018

44. Behar JA, Rosenberg AA, Weiser-Bitoun I, Shemla O, Alexandrovich A, Konynukov E, et al. PhysioZoo: A novel open access platform for heart rate variability analysis of mammalian electrocardiographic data. *Front Physiol* (2018) 9:1390. doi: 10.3389/fphys.2018.012269